Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer
出版年份 2014 全文链接
标题
Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume 137, Issue 2, Pages 267-277
出版商
Wiley
发表日期
2014-12-05
DOI
10.1002/ijc.29378
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Predictive Value of PTEN and AR Coexpression of Sustained Responsiveness to Hormonal Therapy in Prostate Cancer—A Pilot Study
- (2015) Soha Salama El Sheikh et al. NEOPLASIA
- Molecular Pathways: HER3 Targeted Therapy
- (2014) K. Gala et al. CLINICAL CANCER RESEARCH
- Antibody-drug conjugates targeting prostate-specific membrane antigen
- (2014) William Olson Frontiers in Bioscience-Landmark
- Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
- (2013) G. D. L. Phillips et al. CLINICAL CANCER RESEARCH
- Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
- (2013) Jeffrey C Kang et al. mAbs
- Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells
- (2012) Francesca Belleudi et al. CELL CYCLE
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
- (2012) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells
- (2012) P Kharaziha et al. Cell Death & Disease
- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3
- (2011) L. Chen et al. CLINICAL CANCER RESEARCH
- HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer
- (2011) I. Ahmad et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis
- (2010) Andrea Alimonti et al. JOURNAL OF CLINICAL INVESTIGATION
- Loss of PTEN Permits CXCR4-Mediated Tumorigenesis through ERK1/2 in Prostate Cancer Cells
- (2010) M. A. Chetram et al. MOLECULAR CANCER RESEARCH
- Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
- (2010) Y Liu et al. ONCOGENE
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
- (2009) Todd Morgan et al. CURRENT CANCER DRUG TARGETS
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
- (2009) F. I. Raynaud et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
- (2009) B. Schoeberl et al. Science Signaling
- Analyses of the Recycling Receptor, FcRn, in Live Cells Reveal Novel Pathways for Lysosomal Delivery
- (2009) Zhuo Gan et al. TRAFFIC
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
- (2009) William P Harris et al. Nature clinical practice. Urology
- The ERBB3 receptor in cancer and cancer gene therapy
- (2008) G Sithanandam et al. CANCER GENE THERAPY
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
- (2008) N. Rhodes et al. CANCER RESEARCH
- Neuregulins and Cancer
- (2008) J. C. Montero et al. CLINICAL CANCER RESEARCH
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now